Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.

@article{Jeganathan2009SafetyAE,
  title={Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.},
  author={V. Swetha E. Jeganathan and Nitin Verma},
  journal={Current opinion in ophthalmology},
  year={2009},
  volume={20 3},
  pages={223-5}
}
PURPOSE OF REVIEW To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD). RECENT FINDINGS Injecting antivascular endothelial growth factor drugs into the vitreal cavity brings new hope to many AMD patients. Currently, several antivascular endothelial growth factor drugs such as pegaptanib, ranibizumab, and bevacizumab are used via the intravitreal route for neovascular AMD. However, these injections are not without ocular or systemic… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie • 2012
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Ranibizumab for neovascular age-related macular degeneration.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2008

Bevacizumab for neovascular ocular diseases

G Weigert, S Michels, S Sacu
Ann Pharmacother • 2007

Emerging therapies for neovascular age-related macular degeneration: state of the art.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde • 2007

Similar Papers

Loading similar papers…